Clinical Trial Update: Optimizing PTCy Dose and Timing [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 1/2 study aiming to optimize the dose and timing of post-transplant cyclophosphamide to prevent graft-vers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Neoplasms

Drugs mentioned

• Cyclophosphamide (post-transplant regimen) (cyclophosphamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Graft Versus Host Disease, Hematologic Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING